The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.

While the FPG results with evening dosing did not reach statistical significance, the magnitude of effect was generally similar to those in the other active treatment groups, and the lack of significance may reflect the relatively small numbers of patients per treatment group.

also in 111,027 other papers